Sakar Healthcare Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 10, 2025, 11:05 pm

Competitors of Sakar Healthcare Ltd

All Competitor Stocks of Sakar Healthcare Ltd

Quarterly Result

Last Updated: August 1, 2025, 12:55 pm

Below is a detailed analysis of the quarterly data for Sakar Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 52.74 Cr.. The value appears strong and on an upward trend. It has increased from 50.24 Cr. (Mar 2025) to 52.74 Cr., marking an increase of 2.50 Cr..
• For Expenses, as of Jun 2025, the value is 40.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.52 Cr. (Mar 2025) to 40.03 Cr., marking an increase of 5.51 Cr..
• For Operating Profit, as of Jun 2025, the value is 12.71 Cr.. The value appears to be declining and may need further review. It has decreased from 15.72 Cr. (Mar 2025) to 12.71 Cr., marking a decrease of 3.01 Cr..
• For OPM %, as of Jun 2025, the value is 24.10%. The value appears to be declining and may need further review. It has decreased from 31.29% (Mar 2025) to 24.10%, marking a decrease of 7.19%.
• For Other Income, as of Jun 2025, the value is 0.39 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Mar 2025) to 0.39 Cr., marking an increase of 0.21 Cr..
• For Interest, as of Jun 2025, the value is 2.14 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.19 Cr. (Mar 2025) to 2.14 Cr., marking a decrease of 2.05 Cr..
• For Depreciation, as of Jun 2025, the value is 5.57 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.48 Cr. (Mar 2025) to 5.57 Cr., marking an increase of 0.09 Cr..
• For Profit before tax, as of Jun 2025, the value is 5.39 Cr.. The value appears to be declining and may need further review. It has decreased from 6.23 Cr. (Mar 2025) to 5.39 Cr., marking a decrease of 0.84 Cr..
• For Tax %, as of Jun 2025, the value is 13.17%. The value appears to be increasing, which may not be favorable. It has increased from 7.70% (Mar 2025) to 13.17%, marking an increase of 5.47%.
• For Net Profit, as of Jun 2025, the value is 4.67 Cr.. The value appears to be declining and may need further review. It has decreased from 5.76 Cr. (Mar 2025) to 4.67 Cr., marking a decrease of 1.09 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.13. The value appears to be declining and may need further review. It has decreased from 2.62 (Mar 2025) to 2.13, marking a decrease of 0.49.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 2:09 pm

Growth

Last Updated: September 5, 2025, 1:15 pm

Balance Sheet

Last Updated: October 10, 2025, 2:53 pm

Below is a detailed analysis of the balance sheet data for Sakar Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
• For Reserves, as of Mar 2025, the value is 264.00 Cr.. The value appears strong and on an upward trend. It has increased from 241.00 Cr. (Mar 2024) to 264.00 Cr., marking an increase of 23.00 Cr..
• For Borrowings, as of Mar 2025, the value is 86.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 79.00 Cr. (Mar 2024) to 86.00 Cr., marking an increase of 7.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 43.00 Cr.. The value appears to be improving (decreasing). It has decreased from 47.00 Cr. (Mar 2024) to 43.00 Cr., marking a decrease of 4.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 415.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 389.00 Cr. (Mar 2024) to 415.00 Cr., marking an increase of 26.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 314.00 Cr. (Mar 2024) to 309.00 Cr., marking a decrease of 5.00 Cr..
• For CWIP, as of Mar 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 17.00 Cr., marking an increase of 17.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 74.00 Cr. (Mar 2024) to 90.00 Cr., marking an increase of 16.00 Cr..
• For Total Assets, as of Mar 2025, the value is 415.00 Cr.. The value appears strong and on an upward trend. It has increased from 389.00 Cr. (Mar 2024) to 415.00 Cr., marking an increase of 26.00 Cr..

Notably, the Reserves (264.00 Cr.) exceed the Borrowings (86.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Sakar Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.63 (Mar 24) to 7.97, marking an increase of 2.34.
• For Diluted EPS (Rs.), as of Mar 25, the value is 7.95. This value is within the healthy range. It has increased from 5.63 (Mar 24) to 7.95, marking an increase of 2.32.
• For Cash EPS (Rs.), as of Mar 25, the value is 17.49. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 17.49, marking an increase of 3.83.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 130.06. It has increased from 120.61 (Mar 24) to 130.06, marking an increase of 9.45.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 130.06. It has increased from 120.61 (Mar 24) to 130.06, marking an increase of 9.45.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 80.90. It has increased from 70.51 (Mar 24) to 80.90, marking an increase of 10.39.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 19.10 (Mar 24) to 23.23, marking an increase of 4.13.
• For PBIT / Share (Rs.), as of Mar 25, the value is 13.72. This value is within the healthy range. It has increased from 10.80 (Mar 24) to 13.72, marking an increase of 2.92.
• For PBT / Share (Rs.), as of Mar 25, the value is 9.81. This value is within the healthy range. It has increased from 7.31 (Mar 24) to 9.81, marking an increase of 2.50.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.37 (Mar 24) to 7.97, marking an increase of 2.60.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.37 (Mar 24) to 7.97, marking an increase of 2.60.
• For PBDIT Margin (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has increased from 27.08 (Mar 24) to 28.71, marking an increase of 1.63.
• For PBIT Margin (%), as of Mar 25, the value is 16.95. This value is within the healthy range. It has increased from 15.31 (Mar 24) to 16.95, marking an increase of 1.64.
• For PBT Margin (%), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 10.36 (Mar 24) to 12.12, marking an increase of 1.76.
• For Net Profit Margin (%), as of Mar 25, the value is 9.85. This value is within the healthy range. It has increased from 7.61 (Mar 24) to 9.85, marking an increase of 2.24.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.85. This value is within the healthy range. It has increased from 7.61 (Mar 24) to 9.85, marking an increase of 2.24.
• For Return on Networth / Equity (%), as of Mar 25, the value is 6.13. This value is below the healthy minimum of 15. It has increased from 4.44 (Mar 24) to 6.13, marking an increase of 1.69.
• For Return on Capital Employeed (%), as of Mar 25, the value is 8.55. This value is below the healthy minimum of 10. It has increased from 7.12 (Mar 24) to 8.55, marking an increase of 1.43.
• For Return On Assets (%), as of Mar 25, the value is 4.21. This value is below the healthy minimum of 5. It has increased from 3.00 (Mar 24) to 4.21, marking an increase of 1.21.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 0.2. It has decreased from 0.20 (Mar 24) to 0.18, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.26. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.26.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.42 (Mar 24) to 0.44, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.40, marking an increase of 0.19.
• For Quick Ratio (X), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 1. It has decreased from 0.74 (Mar 24) to 0.71, marking a decrease of 0.03.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.68, marking an increase of 2.68.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 5.97. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 5.97, marking an increase of 0.50.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.06. This value is within the healthy range. It has increased from 2.54 (Mar 24) to 3.06, marking an increase of 0.52.
• For Enterprise Value (Cr.), as of Mar 25, the value is 539.37. It has decreased from 869.42 (Mar 24) to 539.37, marking a decrease of 330.05.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has decreased from 5.67 (Mar 24) to 3.04, marking a decrease of 2.63.
• For EV / EBITDA (X), as of Mar 25, the value is 10.58. This value is within the healthy range. It has decreased from 20.93 (Mar 24) to 10.58, marking a decrease of 10.35.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.62. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 2.62, marking a decrease of 2.60.
• For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 3.05 (Mar 24) to 1.63, marking a decrease of 1.42.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.62. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 2.62, marking a decrease of 2.60.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness